Affiliation:
1. Department of Microbiology, Kyoto Pharmaceutical University, Yamashina-ku, Japan.
Abstract
The in vitro activity of the new fluoroquinolone HSR-903 was compared with those of ciprofloxacin, lomefloxacin, sparfloxacin, and levofloxacin. HSR-903 inhibited 90% of methicillin-susceptible and -resistant Staphylococcus aureus (MRSA) clinical isolates at 0.78 and 1.56 microg/ml, respectively, and its activity against MRSA was 16-fold higher than those of sparfloxacin and levofloxacin and 64-fold higher than that of ciprofloxacin. The MICs at which 90% of the isolates are inhibited (MIC90s) of HSR-903 for Streptococcus pyogenes and penicillin G-susceptible and -resistant Streptococcus pneumoniae (PRSP) were 0.10, 0.05, and 0.05 microg/ml, respectively. Against PRSP, the activity of HSR-903 was 4-fold higher than that of sparfloxacin and 32- to 256-fold higher than those of the other quinolones. The MIC90 of HSR-903 for Enterococcus faecalis was 0.20 microg/ml, and HSR-903 was more active than the other quinolones against enterococci. The activity of HSR-903 against members of the family Enterobacteriaceae and Pseudomonas aeruginosa was roughly similar to that of ciprofloxacin and greater than those of the other quinolones. Against Haemophilus influenzae, Moraxella catarrhalis, and Helicobacter pylori, HSR-903 was the most potent of the quinolones tested. The activity of HSR-903 was not affected by the medium, the inoculum size, or the addition of serum, but decreased under acidic conditions, as did those of the other quinolones tested. HSR-903 exhibited rapid bactericidal action and had a good postantibiotic effect on S. aureus and P. aeruginosa. HSR-903 inhibited supercoiling by DNA gyrase from Escherichia coli, but it was much less active against human topoisomerase II.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference19 articles.
1. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus;Blumberg H. M.;J. Infect. Dis.,1991
2. Craig W. A. and S. Gudmundsson. 1991. The postantibiotic effect p. 403-431. In V. Lorian (ed.) Antibiotics in laboratory medicine. Williams & Wilkins Baltimore Md.
3. Structure-activity and structure-side-effect relationships for the quinolone antibacterials;Domagala J. M.;J. Antimicrob. Chemother.,1994
4. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone;Fujimaki K.;Antimicrob. Agents Chemother.,1988
5. In vitro and in vivo activity of NY-198, a new difluorinated quinolone;Hirose T.;Antimicrob. Agents Chemother.,1987
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献